BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Transl Oncol
Huvudupphovsmän: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Materialtyp: Artigo
Språk:Inglês
Publicerad: Neoplasia Press 2016
Ämnen:
Original article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://ncbi.nlm.nih.gov/pubmed/27267837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.03.008
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk